TABLE 12 Incidence of Malaria from Randomization Up to 5 Months After the Last Dose of SP

Location, Country

Ifakara, Tanzania

Navrongo, Ghana

Manhiça, Mozambique

Kumasi, Ghana

Lambaréné, Gabon

Tamale, Ghana

Overall

Placebo

Episodes

158

1419

380

910

93

891

 

PYAR

288

1398

540

614

558

667

 

Incidence

0.55

1.01

0.70

1.48

0.17

1.34

 

IPTi with SP

Episodes

75

1068

269

770

82

711

 

PYAR

291

1403

546

620

577

668

 

Incidence

0.26

0.76

0.68

1.24

0.14

1.06

 

Efficacy (95% CI)

55 (27, 68)

25 (14, 35)

5 (−18, 24)

16 (8, 24)

13 (−26, 40)

21 (10, 30)

21 (11, 29)

p-value

<0.001

<0.001

0.64

<0.001

0.46

<0.001

<0.001

NOTE: PYAR: Person-years at risk

SOURCE: Compiled from data in the Report of the Statistical Working Group (IPTi Consortium, 2007b).

TABLE 13 Risk of Anemia from Randomization Up to 5 Months After the Last Dose of SP

Location, Country

Ifakara, Tanzania

Navrongo, Ghana

Manhiça, Mozambique

Kumasi, Ghana

Lambaréné, Gabon

Tamale, Ghana

Overall

Placebo

Episodes

31

234

87

316

110

347

 

Subjects

351

1225

748

535

507

599

 

Risk (%)

9

19

12

59

22

58

 

IPTi with SP

Episodes

22

215

103

291

86

319

 

Subjects

350

1221

755

535

504

600

 

Risk (%)

6

18

14

54

17

53

 

Efficacy (95% CI)

29 (−29, 58)

8 (−15, 26)

15 (−11, 35)

9 (−8, 22)

21 (−1, 39)

8 (−2, 17)

10 (4, 17)

p-value

0.21

0.47

0.24

0.31

0.06

0.10

0.003

NOTE: The committee used Stata to calculate the overall efficacy and its 95 percent confidence limit.

SOURCE: Data from the Report of the Statistical Working Group (IPTi Consortium, 2007b).



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement